secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0001193125-23-218062
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis updates on 8 retinal vasculitis events with SYFOVRE; recommends switching to 18-gauge filter needle
--------------------------------------------------------------------------------

- Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.
- Last confirmed event on June 20; over 32,000 vials distributed since then with no new confirmed events.
- One additional occlusive event in May reported after July 29; all events occurred after first injection.
- Company recommends discontinuing use of 19-gauge filter needle kits; now exclusively distributing 18-gauge filter needle kits.
- Patient outcomes: 1 stable, 2 near baseline, 2 severe vision impairment, 3 pending; two suspected events also reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/0001193125-23-218062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523218062/d539134d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-218062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer